title: Albumin dialysis: single pass vs. recirculation (MARS).
abstract: The single pass albumin dialysis (SPAD) was reported to be an alternative to the Molecular Adsorbent Recirculating System (MARS) for the effective removal of protein bound substances in liver failure. Three SPAD experiments using different albumin concentrations and dialysate flow rates were performed. In each experiment, 1000 ml human donor plasma, spiked with 250 mg unconjugated bilirubin, 200 mg sulfobromophthalein (BSP) and 115 mg glycocholic acid (N-[3alpha,7alpha,12alpha-trihydroxy-24-oxycholan-24-yl]glycine) - a conjugated bile acid (BA), circulated in a closed loop with 150 ml/min and was dialysed against albumin solution. These substances are bound to the different binding sites of albumin and have different association constants. For the comparison, the standard MARS experiment was performed using the same plasma flow rate of 150 ml/min. Moreover, the clearances of bilirubin for MARS and SPAD during clinical treatments were calculated using own data and those reported by Seige, Kreymann, Jeschke, et al. in Transplant Proc 1999; 31: 1371-5. The concentrations of bilirubin, BSP and BA were measured in plasma and dialysate and for these substances clearances (Cl) were calculated. It is known that the elimination rate of bilirubin is not very high during albumin dialysis in comparison to other substances, like bile acids, due to the high association constant. An increase of albumin concentration or the flow rate improved the efficacy but also raised the costs substantially. In this study, we have shown that MARS is the more effective kind of albumin dialysis for the important substances like bile acids. By SPAD an improvement of efficacy can be reached only by dramatic increase of the costs. Also, the earlier experiments showed that MARS is safer because of the removal of the stabilizers, which are normally included in the commercial albumin solutions.
authors.affiliation: Department of Internal Medicine, University of Rostock, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Peszynski
authors.forename: S
authors.initials: S
authors.lastname: Klammt
authors.forename: E
authors.initials: E
authors.lastname: Peters
authors.forename: S
authors.initials: S
authors.lastname: Mitzner
authors.forename: J
authors.initials: J
authors.lastname: Stange
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
mesh_terms: D001647:Bile Acids and Salts / Q000097:blood; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000628:therapy*; D006435:Renal Dialysis / Q000379:methods*; D012709:Serum Albumin / Q000378:metabolism*; D016060:Sorption Detoxification / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D001647:Bile Acids and Salts; D012709:Serum Albumin